Use of troponin to diagnose periprocedural myocardial infarction: effect on composite endpoints in the British Bifurcation Coronary Study (BBC ONE)


Cockburn, J; Behan, M; de Belder, A; Clayton, T; Stables, R; Oldroyd, K; Curzen, N; Hildick-Smith, D; (2012) Use of troponin to diagnose periprocedural myocardial infarction: effect on composite endpoints in the British Bifurcation Coronary Study (BBC ONE). Heart (British Cardiac Society), 98 (19). pp. 1431-1435. ISSN 1355-6037 DOI: https://doi.org/10.1136/heartjnl-2012-302211

Full text not available from this repository.

Abstract

Background Periprocedural myocardial infarction (PMI; ESC/ACC type 4a) is diagnosed on the basis of elevation of cardiac enzymes more than three times the 99th centile upper reference limit. Recent guidelines recommend the use of troponin instead of creatine kinase (CK) to diagnose PMI, but this assay increases diagnostic sensitivity, while the clinical significance of small increases in troponin remains undetermined. We examined the effects of using the new definition on the incidence of a composite endpoint (previously defined by CK) in a contemporary clinical randomised trial-the British Bifurcation Coronary Study (BBC ONE). Methods The BBC ONE trial randomly allocated 500 patients with coronary bifurcation lesions to either a simple or complex stenting strategy. The composite primary endpoint (CPEP) included death, myocardial infarction (MI) (PMI plus subsequent MI) and target vessel failure, at 9 months. Results In BBC ONE the CPEP occurred in 8% versus 15.2% in the simple and complex groups, respectively (HR 2.02, 95% CI 1.17 to 3.47, p = 0.009). This difference was largely driven by PMI, which occurred in nine (3.6%) versus 28 (11.2%) patients (HR 3.24, 95% CI 1.53 to 6.86, p = 0.001). Using troponin, PMI would have occurred in 71 (28.4%) versus 114 (45.6%) patients, respectively (HR 1.61, 95% CI 1.27 to 2.05, p 0.001), and the CPEP in 32% versus 48% of patients (HR 1.50, 95% CI 1.2 to 1.87, p = 0.001). Use of troponin increased MI detection fivefold, from 7.4% to 37.0% overall. Conclusions Use of troponin would have led to a fivefold increase in diagnosis of PMI in the BBC ONE trial. Incorporation of PMI into a composite endpoint may no longer be justified in many interventional trials.

Item Type: Article
Keywords: high-sensitivity troponin, kinase-mb elevation, universal definition, stent trials, intervention, revascularization, redefinition, impact, assays, level, Aged, Angioplasty, Balloon, Coronary, adverse effects, instrumentation, mortality, Biological Markers, blood, Coronary Artery Disease, mortality, therapy, Creatine Kinase, MB Form, blood, Female, Great Britain, Humans, Incidence, Kaplan-Meier Estimate, Male, Middle Aged, Multicenter Studies as Topic, Myocardial Infarction, blood, diagnosis, mortality, Predictive Value of Tests, Proportional Hazards Models, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Assessment, Risk Factors, Stents, Time Factors, Treatment Outcome, Troponin I, blood, Troponin T, blood
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Medical Statistics
Research Centre: Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 22851684
Web of Science ID: 308750000009
URI: http://researchonline.lshtm.ac.uk/id/eprint/427598

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
306Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item